Soligenix Announces Partial Adjournment of Annual Meeting and Information for Reconvened Annual Meeting

- Meeting adjourned to October 19, 2022, at 9:00 a.m., Eastern Time- Soligenix encourages all stockholders of record at the close of business on July 25, 2022 who have not yet voted, to vote by 11:59 p.m., Eastern Time on October 18, 2022PRINCETON, N.J., Sept. 23, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its 2022 Annual Meeting of Stockholders (the "Annual Meeting") scheduled for and convened on September 22, 2022 has been partially adjourned for the purpose of soliciting additional votes with respect to Proposal 2, the approval of an amendment to the Company's Second Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 75,000,000 to 125,000,000, as set forth in the Company's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on August 5, 2022 (the "Proxy Statement").A quorum was present at the Annual Meeting, and Proposals One (the election of five directors), Three (the approval of the amendment to the 2015 Equity Incentive Plan), Four (the advisory vote on executive compensation), and Five (the ratification of the appointment of EisnerAmper LLP), set forth in the Proxy Statement, received the requisite votes for approval.The Annual Meeting will be reconvened solely with respect to Proposal 2 on October 19, 2022 at 9:00 a.m. Eastern Time and will continue to be held virtually via live audio-only webcast at
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Октябрь 2022    »